Meadowbrook Advisors Group LLC Makes New Investment in Amgen Inc. $AMGN

Meadowbrook Advisors Group LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 6,416 shares of the medical research company’s stock, valued at approximately $2,100,000. Amgen accounts for about 1.2% of Meadowbrook Advisors Group LLC’s holdings, making the stock its 27th largest position.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. raised its position in shares of Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new position in Amgen during the fourth quarter valued at approximately $1,669,000. Adell Harriman & Carpenter Inc. grew its holdings in Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Amgen in the fourth quarter valued at approximately $22,441,000. Finally, Sigma Planning Corp raised its holdings in Amgen by 24.0% in the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock worth $5,889,000 after purchasing an additional 3,488 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Daiwa Securities Group reduced their price target on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. The Goldman Sachs Group set a $389.00 price objective on Amgen in a research note on Friday, June 5th. Argus decreased their target price on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, Truist Financial increased their price target on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $354.42.

Amgen Price Performance

Amgen stock opened at $337.60 on Friday. The company has a market cap of $182.21 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29. The company has a fifty day simple moving average of $340.71 and a 200 day simple moving average of $345.76. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the previous year, the firm posted $4.90 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.